- Fourth quarter in a row with growth
1 Januay-31 March
- Net sales reached SEK 5,6 (4,6) million
- Loss after taxes SEK -3,2 (-2,1) million
- Earnings per share were SEK -0,06 SEK (-0,04)
- Cash and equivalents were 6,3 (7,9) million
Significant events during period
- CE-mark for the new platform Eagle obtained
- Patent that include the Schelin Catheter is approved
- An agreement with a new clinic in Stockholm was signed
- An agreement with a new clinic in Karlshamn was signed
- Agreement with SLG Kalmar is signed with an order value of SEK 2,4 million
Significant events after the end of the period
- Distribution agreement for Poland was signed
- Schelin Catheter® approved for sale in the province of Hainan in China
- The board decided on May 17th 2023 to carry out a rights issue of approx. 40 MSEK before issue costs
| Key figures | ||||
| (SEK MILLION) | jan-mar 2023 | jan-mar 2022 | jan-mar 2021 | jan-mar 2020 |
| Net sales | 5,6 | 4,6 | 5,3 | 4,6 |
| Gross margin, % | 68 | 81 | 83 | 72 |
| Operating profit/loss | -3,2 | -2,1 | -1,2 | -1,6 |
| Cash flow from operating activities | -5,5 | -5,1 | -2,2 | 1,4 |
| Average number of employees | 9 | 7 | 7 | 5 |
"The first quarter of the year was characterized by the same intensity as 2022. We began the year with continued growth and reported the highest turnover ever during a quarter"
Johan Wennerholm
CEO, ProstaLund AB (publ)
For further information, please contact:
Johan Wennerholm, CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com
About ProstaLund
ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.
Certified Adviser:
Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se
This information is information that ProstaLund AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-05-17 08:15 CEST.
